---
id: chlamydia-pneumoniae_326
category: organisms
tags: [Chlamydia-pneumoniae, TWAR, atypical-pneumonia, CAP, atherosclerosis, macrolides]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Chlamydia pneumoniae

**Q:** What are the clinical features and associations of C. pneumoniae infection?

**A:**

**Overview:**
- **Also known as**: TWAR (Taiwan acute respiratory agent)
- **Obligate intracellular pathogen**
- Cause of **atypical CAP** (up to 20% of cases)

**Epidemiology:**
- **Person-to-person** transmission (respiratory droplets)
- All ages affected (children through elderly)
- **70% asymptomatic** or mild symptoms
- **30% cause** bronchitis, pharyngitis, sinusitis, pneumonia

**Clinical Features:**

| Feature | Details |
|---------|---------|
| **Pneumonia** | **Atypical CAP** (insidious onset, dry cough, low-grade fever); **20% of CAP cases** |
| **Bronchitis** | Persistent cough |
| **Pharyngitis** | Sore throat, hoarseness |
| **Sinusitis** | Often prolonged |

**Key Characteristics:**
- **Prolonged, indolent course** (weeks)
- Often preceded by upper respiratory symptoms (pharyngitis, laryngitis)
- **Biphasic illness** possible

**Diagnosis:**
- **PCR** (respiratory specimens) - preferred
- **Serology**: IgM + IgG (less reliable; widespread seroprevalence makes interpretation difficult)
- Cannot gram stain (intracellular)

**Treatment:**

**Recommended Antibiotics:**
- **Macrolides** (azithromycin, clarithromycin)
- **Tetracyclines** (doxycycline)
- **Fluoroquinolones** (levofloxacin, moxifloxacin)

**Duration:**
- **Prolonged therapy** may be needed (symptoms can return after short course)
- Typically **10-14 days** minimum

**Atherosclerosis Association (Controversial):**

**Observational Evidence:**
- C. pneumoniae DNA/antigens detected in **atherosclerotic plaques**
- Seroprevalence correlates with CAD risk
- Animal models show acceleration of atherosclerosis

**Clinical Trials:**
- **Antibiotic trials for secondary CAD prevention**: **NEGATIVE**
- No proven benefit of antibiotics for atherosclerosis
- Association may reflect **chronic inflammation** rather than causation

**Current Consensus:**
- C. pneumoniae likely **marker** of atherosclerosis, not causative agent
- **NO indication** for antibiotics to treat/prevent CAD

**Key Points:**
- Causes **20% of atypical CAP**
- **Prolonged, indolent course** (weeks)
- Treat with **macrolides, tetracyclines, or fluoroquinolones** × 10-14 days
- Atherosclerosis association: **observational only** (antibiotic trials negative)

**Mnemonic - "TWAR = Tricky Wheeze, Atherosclerosis Research"**: Taiwan acute respiratory agent, atherosclerosis association (observational)

**Pearl:** C. pneumoniae causes 20% of atypical CAP with prolonged, indolent course. Although C. pneumoniae DNA is found in atherosclerotic plaques, antibiotic trials for CAD prevention were negative—likely a marker, not cause.

**Media:**

**Sources:** [StatPearls Chlamydia Pneumonia NBK560874], [PMC7173483 - C. pneumoniae Review], [PMC7118749 - C. pneumoniae and Atherosclerosis], [CDC Atypical Pneumonia Guidelines]
